Edition:
United States

Immune Design Corp (IMDZ.OQ)

IMDZ.OQ on NASDAQ Stock Exchange Global Market

3.75USD
3:59pm EST
Change (% chg)

$0.05 (+1.35%)
Prev Close
$3.70
Open
$3.70
Day's High
$3.80
Day's Low
$3.67
Volume
116,628
Avg. Vol
111,618
52-wk High
$13.00
52-wk Low
$3.55

Chart for

About

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to... (more)

Overall

Beta: 2.37
Market Cap(Mil.): $177.82
Shares Outstanding(Mil.): 48.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-Ecor1 Capital reports 7.4% passive stake in Immune Design

* Ecor1 Capital Llc reports 7.4% passive stake in Immune Design Corp as of Oct 25 - SEC filing‍​ Source text: (http://bit.ly/2zkI4Ki) Further company coverage:

Nov 06 2017

BRIEF-Immune Design reports Q3 loss per share of $0.52

* IMMUNE DESIGN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Nov 01 2017

BRIEF-Immune Design prices offering of 19.5 million shares at $4.10 per share​

* Immune Design prices $80.0 million public offering of common stock

Oct 24 2017

BRIEF-Immune Design proposes public offering of common stock

* Immune Design announces proposed public offering of common stock

Oct 23 2017

BRIEF-Immune design announces G100’s receipt of orphan drug designation by EMA

* Immune design announces G100’S receipt of orphan drug designation by the EMA for the treatment of follicular non-Hodgkin’s lymphoma Source text for Eikon: Further company coverage:

Oct 19 2017

BRIEF-Immune Design gets positive FDA feedback on Phase 3 clinical trial design for CMB305

* Immune Design announces positive FDA feedback on Phase 3 clinical trial design for CMB305 in synovial sarcoma patients

Oct 16 2017

BRIEF-Bain Capital Public Equity Management LLC reports a 5.07 pct passive stake in Immune Design

* Bain Capital Public Equity Management LLC reports a 5.07 percent passive stake in Immune Design Corp as of September 29, 2017 - SEC Filing‍​ Source text:(http://bit.ly/2xnRteZ) Further company coverage:

Oct 06 2017

BRIEF-Immune Design Q2 loss per share $0.54

* Immune Design reports second quarter 2017 financial results and provides corporate update

Aug 02 2017

BRIEF-Immune Design says it may offer shares of up to $50 mln

* Immune design corp - ‍immune design corp. Entered into a sales agreement with cowen and company, llc​

Jul 03 2017

Earnings vs. Estimates